Completed NA INTERVENTIONAL 2-arm NCT01507155

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay (COM-1)

Sponsor: Genomind, LLC

Conditions Generalized Anxiety Disorder Treatment Resistant Depression

Updated 7 times since 2017 Last updated: May 5, 2016 Started: Apr 30, 2013 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Generalized Anxiety Disorder and Treatment Resistant Depression and is currently completed. Genomind, LLC leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genomind, LLC

Data source: Genomind, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chalfont, United States